Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Item Type:Letter
Title:Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Creators Name:Dang, N.H. and Ogura, M. and Castaigne, S. and Fayad, L.E. and Jerkeman, M. and Radford, J. and Pezzutto, A. and Bondarenko, I. and Stewart, D.A. and Shnaidman, M. and Sullivan, S. and Vandendries, E. and Tobinai, K. and Ramchandren, R. and Hamlin, P.A. and Giné, E. and Ando, K.
Keywords:Inotuzumab Ozogamicin, B-Cell Non-Hodgkin Lymphoma, CD22+, Antibody-Drug Conjugate, Rituximab
Source:British Journal of Haematology
ISSN:0007-1048
Publisher:Wiley-Blackwell (U.K.)
Volume:182
Number:4
Page Range:583-586
Date:August 2018
Official Publication:https://doi.org/10.1111/bjh.14820
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library